APOA4 and obesity due to melanocortin 4 receptor deficiency: Given APOA4’s wide range of functions, our findings may serve as the molecular basis for the development of APOA4-targeted therapeutics for diseases such as dyslipidemia, clinical complications of atherosclerosis, diabetes, obesity, Alzheimer’s disease, and other inflammatory conditions.